MAQS advises BrainZell on capital raising

MAQS has provided advisory services to BrainZell in connection with its successful capital raise. 

BrainZell secured 15 million SEK in an investment round led by Industrifonden, with participation from Life Science Invest, Norrsken Accelerator, Creator Fund, and several angel investors. 

BrainZell, a Swedish start-up, is at the forefront of drug discovery with its groundbreaking brain organoid technology. Powered by stem cell-derived miniature models of the human brain, BrainZell shapes the future of brain health and medicine.

The MAQS team was led by Sara Malmström and Joel Lundgren.